George Simon, MD, FACP, FCCP
Dr. George Simon is an internationally respected medical oncologist and specialist in lung cancer and pleural mesothelioma. He is the Vice President of Oncology Services at OhioHealth.[1]
Education and Career
Dr. Simon earned his medical degree at the Christian Medical College and Hospital in Punjab, India. After completing a residency in Internal Medicine there, he pursued an additional residency in Internal Medicine at St. Joseph’s Hospital in Denver, Colorado, followed by a fellowship in Medical Oncology and Hematology at the University of Colorado Health Sciences Center in Denver.[2]
Upon completion of his medical education and training, Dr. Simon served as a faculty member and member of the Department of Thoracic Oncology, as well as director of mesothelioma research at Moffitt Cancer Center.
He also held director-level positions at Fox Chase Cancer Center in Philadelphia and the Hollings Cancer Center in Charleston, South Carolina, and as medical director of the MD Anderson Cancer Network.
He served as section chief of translational research in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center in Houston, Texas.[1]
Dr. Simon is currently the Vice President of Oncology Services for OhioHealth, a position he took in 2025. He has special expertise in non-small cell lung cancer, mesothelioma, thymoma, and personalized cancer treatments.
Dr. Simon has also served on guideline panels for the American College of Chest Physicians and the National Comprehensive Cancer Network. He is a member of the American Society of Oncology and the American College of Physicians. He holds two U.S. patents and is a leader in cancer research.
Research
Dr. Simon’s research interests include early drug development, DNA repair, tumor metabolism, and epigenetic modulation of cancer.
He has served as a reviewer for several panels of the National Institutes of Health and the National Cancer Institute, the Department of Defense, and the Veterans Administration Merit Review Board. He has also been an international grant reviewer for the NICE, UK, and for granting organizations in Ireland and Australia.
Dr. Simon has published more than 100 peer-reviewed articles, including the following recent works:
- Patz EF, Gottlin EB, Simon GR. Perspective: rethinking therapeutic strategies in oncology. Front Oncol. 2024 Jan.13:1335987. Pubmedid: 38269024. Pmcid: PMC10805859.
- Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
- Piha-Paul S, Simon G, Belani CP, Chao H, Gaspar K, Lee B, Dowlati A. A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC. JTO Clin Res Rep. 2022 Nov.3(11):100408. Pubmedid: 36268537. Pmcid: PMC9576893.
- Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep. 2021 Nov.2(11):100237. Pubmedid: 34820641. Pmcid: PMC8600084.
- Theelen WSME, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts JGJV, Bahce I, Niemeijer ALN, Chang JY, de Groot PM, Nguyen QN, Comeaux NI, Simon GR, Skoulidis F, Lin SH, He K, Patel R, Heymach J, Baas P, Welsh JW. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 May.9(5):467-475. Pubmedid: 33096027.
